JP2022531809A5 - - Google Patents
Info
- Publication number
- JP2022531809A5 JP2022531809A5 JP2021567820A JP2021567820A JP2022531809A5 JP 2022531809 A5 JP2022531809 A5 JP 2022531809A5 JP 2021567820 A JP2021567820 A JP 2021567820A JP 2021567820 A JP2021567820 A JP 2021567820A JP 2022531809 A5 JP2022531809 A5 JP 2022531809A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- seq
- item
- composition
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962847416P | 2019-05-14 | 2019-05-14 | |
| US62/847,416 | 2019-05-14 | ||
| PCT/US2020/032978 WO2020232297A1 (en) | 2019-05-14 | 2020-05-14 | Compositions and methods for the treatment of atpase-mediated diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022531809A JP2022531809A (ja) | 2022-07-11 |
| JP2022531809A5 true JP2022531809A5 (https=) | 2023-05-16 |
Family
ID=73289760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021567820A Pending JP2022531809A (ja) | 2019-05-14 | 2020-05-14 | ＡＴＰａｓｅ媒介性疾患の処置のための組成物および方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11717560B2 (https=) |
| EP (1) | EP3969597A4 (https=) |
| JP (1) | JP2022531809A (https=) |
| KR (1) | KR20220032005A (https=) |
| CN (1) | CN114072514A (https=) |
| AU (1) | AU2020274200A1 (https=) |
| BR (1) | BR112021022951A2 (https=) |
| CA (1) | CA3140049A1 (https=) |
| IL (1) | IL287796A (https=) |
| MX (1) | MX2021013913A (https=) |
| SG (1) | SG11202112078TA (https=) |
| WO (1) | WO2020232297A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3774852A1 (en) | 2018-04-03 | 2021-02-17 | Stridebio, Inc. | Antibody-evading virus vectors |
| MX2020010465A (es) | 2018-04-03 | 2021-01-08 | Vectores de virus para direccionamiento a tejidos oftalmicos. | |
| AU2019247748A1 (en) | 2018-04-03 | 2020-10-08 | Ginkgo Bioworks, Inc. | Antibody-evading virus vectors |
| AR118465A1 (es) | 2019-03-21 | 2021-10-06 | Stridebio Inc | Vectores de virus adenoasociados recombinantes |
| CA3140049A1 (en) * | 2019-05-14 | 2020-11-19 | Duke University | Compositions and methods for the treatment of atpase-mediated diseases |
| US12611436B2 (en) | 2019-10-17 | 2026-04-28 | Sarepta Therapeutics, Inc. | AAV transfer cassette |
| JP2022551739A (ja) | 2019-10-17 | 2022-12-13 | ストライドバイオ，インコーポレイテッド | ニーマン・ピック病ｃ型の治療のためのアデノ随伴ウイルスベクター |
| AU2021328475A1 (en) | 2020-08-19 | 2023-03-16 | Sarepta Therapeutics, Inc. | Adeno-associated virus vectors for treatment of Rett syndrome |
| TW202323528A (zh) * | 2021-10-18 | 2023-06-16 | 美商邏輯生物療法公司 | 用於治療威爾森氏病之基因療法 |
| US20250320509A1 (en) * | 2022-05-23 | 2025-10-16 | The Johns Hopkins University | Compositions and methods for treating wilson's disease |
| CN115851730A (zh) * | 2022-11-16 | 2023-03-28 | 泰达国际心血管病医院 | Myh6基因启动子变异及其应用与先天性心脏病基因检测试剂盒 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001046226A2 (en) * | 1999-12-22 | 2001-06-28 | Aventis Pasteur Limited | Chlamydia antigens and corresponding dna fragments and uses thereof |
| US7473531B1 (en) * | 2003-08-08 | 2009-01-06 | Colora Corporation | Pancreatic cancer targets and uses thereof |
| WO2007011682A2 (en) * | 2005-07-15 | 2007-01-25 | Regents Of The University Of California | Methods and reagents for screening new drugs and for treating ion pump associated disorders and diseases |
| WO2010144611A2 (en) * | 2009-06-10 | 2010-12-16 | 3-V Biosciences, Inc. | Antivirals that target transporters, carriers, and ion channels |
| CN107080847A (zh) * | 2011-06-24 | 2017-08-22 | 森彻斯有限公司 | 细胞外靶向药物缀合物 |
| WO2014007868A2 (en) | 2012-03-15 | 2014-01-09 | The Regents Of The University Of California | Low temperature sulfur and sodium metal battery for grid-scale energy storage application |
| US20140350087A9 (en) * | 2012-03-22 | 2014-11-27 | Halozyme, Inc. | Oncovector Nucleic Acid Molecules and Methods of Use |
| WO2013151665A2 (en) * | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins associated with human disease |
| RU2679843C2 (ru) * | 2012-07-06 | 2019-02-13 | Юниверсити Оф Айова Рисерч Фаундейшн | Векторные композиции с модифицированным аденоассоциированным вирусом |
| AU2013293270B2 (en) * | 2012-07-25 | 2018-08-16 | Massachusetts Institute Of Technology | Inducible DNA binding proteins and genome perturbation tools and applications thereof |
| EP2952898B1 (en) * | 2014-06-06 | 2018-08-08 | Euroimmun Medizinische Labordiagnostika AG | Diagnosis of a neurological disease |
| US11147887B2 (en) * | 2014-12-17 | 2021-10-19 | Fundación Para La Investigación Mèdica Aplicada | Nucleic acid constructs and gene therapy vectors for use in the treatment of Wilson disease |
| WO2017013648A1 (en) * | 2015-07-19 | 2017-01-26 | Yeda Research And Development Co. Ltd. | SELECTIVE INHIBITORS OF Alpha2-CONTAINING ISOFORMS OF Na,K-ATPase AND USE THEREOF FOR REDUCTION OF INTRAOCULAR PRESSURE |
| JP7049249B2 (ja) * | 2015-12-14 | 2022-04-06 | コールド スプリング ハーバー ラボラトリー | 中枢神経系疾患の処置のための組成物および方法 |
| JP2020534788A (ja) * | 2017-08-28 | 2020-12-03 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | アデノ随伴ウイルスカプシド変異体及びその使用方法 |
| WO2019199841A1 (en) * | 2018-04-09 | 2019-10-17 | Cure Ahc, Inc. | Aav-mediated delivery of atp1a3 genes to central nervous system |
| DK3906066T5 (da) * | 2019-01-04 | 2024-08-05 | Ultragenyx Pharmaceutical Inc | Geneterapikonstruktioner til behandling af wilsons sygdom |
| CA3140049A1 (en) * | 2019-05-14 | 2020-11-19 | Duke University | Compositions and methods for the treatment of atpase-mediated diseases |
-
2020
- 2020-05-14 CA CA3140049A patent/CA3140049A1/en active Pending
- 2020-05-14 AU AU2020274200A patent/AU2020274200A1/en not_active Abandoned
- 2020-05-14 SG SG11202112078TA patent/SG11202112078TA/en unknown
- 2020-05-14 WO PCT/US2020/032978 patent/WO2020232297A1/en not_active Ceased
- 2020-05-14 CN CN202080047216.7A patent/CN114072514A/zh active Pending
- 2020-05-14 KR KR1020217040927A patent/KR20220032005A/ko not_active Withdrawn
- 2020-05-14 BR BR112021022951A patent/BR112021022951A2/pt not_active Application Discontinuation
- 2020-05-14 JP JP2021567820A patent/JP2022531809A/ja active Pending
- 2020-05-14 MX MX2021013913A patent/MX2021013913A/es unknown
- 2020-05-14 EP EP20805008.8A patent/EP3969597A4/en active Pending
-
2021
- 2021-11-02 IL IL287796A patent/IL287796A/en unknown
- 2021-11-11 US US17/524,466 patent/US11717560B2/en active Active
-
2023
- 2023-06-23 US US18/340,028 patent/US12533397B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022531809A5 (https=) | ||
| US11674156B2 (en) | Adeno-associated virus virion for gene transfer to nervous system cells | |
| US12533397B2 (en) | Methods of treating ATPase-mediated diseases with a nucleic acid encoding ATP1A3 and a neuron-specific promoter | |
| US12037588B2 (en) | Compositions and methods comprising engineered short nuclear RNA (snRNA) | |
| JP7702949B2 (ja) | ヒトｍｅｃｐ２遺伝子を発現するように設計されたトランスジーンカセット | |
| JP2022541070A5 (https=) | ||
| JP2023537980A5 (https=) | ||
| JP2023537358A5 (https=) | ||
| JP2025540074A (ja) | 繰り返しエレメントの適切なパッケージングのためのアデノ随伴ウイルスベクター | |
| JP2021534766A5 (https=) | ||
| KR20230004617A (ko) | 신경계 장애를 치료하기 위한 조성물 및 방법 | |
| WO2025162449A1 (en) | Compositions and methods for the treatment of heart disease | |
| JP2022523320A5 (https=) | ||
| US20260002176A1 (en) | Adeno-associated virus gene therapy products and methods | |
| JP2025508177A (ja) | 制御された筋肉特異的遺伝子送達 | |
| EA052057B1 (ru) | КОМПОЗИЦИИ И СПОСОБЫ, ВКЛЮЧАЮЩИЕ СКОНСТРУИРОВАННУЮ МАЛУЮ ЯДЕРНУЮ РНК (snРНК) | |
| TW202546236A (zh) | 用於治療第1型肌強直性營養不良之肌肉選擇性混合調節組合及其使用方法 | |
| RU2021117249A (ru) | Модулирующие полинуклеотиды | |
| RU2023132088A (ru) | Получение улучшенной человеческой pah для лечения тяжелой pku с помощью генной заместительной терапии, направленной на печень |